We could cut R&D spending by 75% over the next 5 years and use the savings to repeat our successes from 18 years ago. Mega-hits Aricept, Lipitor, Zyvox, Zyrtex, Celebrex, Bextra and our pain franchise, our oncology franchise (plus many, many more) all came from our buyouts of former competitors.
Janssen could be next. The Pfizer M.O. is: buy successful companies, take their successes away from them and then lay them all off.
Wasn't the whole idea of this massive reorg into three business units done to sell off pieces of this company. We just sold nutrition, spun off animal health. We will be selling off more in the next three years. Not sure if buying anything is in the cards (except stock buy backs). Maybe another King-like acquisition…hmmmm!! That worked out well.